Lyell Immunopharma is a biotechnology business based in the US. Lyell Immunopharma shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Lyell Immunopharma employs 219 staff and has a trailing 12-month revenue of around $39.1 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $3.28 |
|---|---|
| 52-week range | $2.74 - $8.74 |
| 50-day moving average | $3.62 |
| 200-day moving average | $5.45 |
| Wall St. target price | $9.00 |
| PE ratio | 2.1701 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.47 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.28 from 2023-01-26
| 1 week (2023-01-20) | 9.70% |
|---|---|
| 1 month (2022-12-28) | 13.89% |
| 3 months (2022-10-28) | -46.32% |
| 6 months (2022-07-28) | -41.74% |
| 1 year (2022-01-28) | -37.52% |
|---|---|
| 2 years (2021-01-24) | N/A |
| 3 years (2020-01-24) | N/A |
| 5 years (2018-01-24) | N/A |
Valuing Lyell Immunopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lyell Immunopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lyell Immunopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Lyell Immunopharma shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Lyell Immunopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Revenue TTM | $39.1 million |
|---|---|
| Gross profit TTM | $10.7 million |
| Return on assets TTM | -12.57% |
| Return on equity TTM | -28.61% |
| Profit margin | 0% |
| Book value | $3.29 |
| Market capitalisation | $795.3 million |
TTM: trailing 12 months
We're not expecting Lyell Immunopharma to pay a dividend over the next 12 months.
Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
